![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Rammelkamp Center for Education and Research, MetroHealth Campus, Case Western Reserve University, Cleveland, Ohio (E.F., Y.A.K., A.T.D., L.W., A.M.B.); Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, Ohio (C.O.-P.); and ChanTest, Inc., Cleveland, Ohio (P.H., B.A.W.)
Arsenic trioxide (As2O3) produces dramatic remissions in patients with relapsed or refractory acute promyelocytic leukemia. Its clinical use is burdened by QT prolongation, torsade de pointes, and sudden cardiac death. In the present study, we analyzed the molecular mechanisms leading to As2O3-induced abnormalities of cardiac electrophysiology. Using biochemical and electrophysiological methods, we show that long-term exposure to As2O3 increases cardiac calcium currents and reduces surface expression of the cardiac potassium channel human ether-a-go-go-related gene (HERG) at clinically relevant concentrations of 0.1 to 1.5 µM. In ventricular myocytes, As2O3 increases action potential duration measured at 30 and 90% of repolarization. As2O3 interferes with hERG trafficking by inhibition of hERG-chaperone complexes and increases calcium currents by a faster cellular process. We propose that an increase in cardiac calcium current and reduced trafficking of hERG channels to the cell surface cause QT prolongation and torsade de pointes in patients treated with As2O3. Our results suggest that calcium-channel antagonists will be useful in normalizing QT prolongation during As2O3 therapy. As2O3 is the first example of a drug that produces hERG liability by inhibition of ion-channel trafficking. Other drugs that interfere with proteins in the processing pathway of cardiac ion channels may be proarrhythmic for similar reasons.
Received September 22, 2003; accepted March 11, 2004.
Address correspondence to: Dr. Eckhard Ficker, Rammelkamp Center, MetroHealth Medical Center, 2500 MetroHealth Drive, Cleveland, OH 44109. E-mail: eficker{at}metrohealth.org
This article has been cited by other articles:
|
|
 |
|
  I. Mordukhovich, R. O. Wright, C. Amarasiriwardena, E. Baja, A. Baccarelli, H. Suh, D. Sparrow, P. Vokonas, and J. Schwartz Association Between Low-Level Environmental Arsenic Exposure and QT Interval Duration in a General Population Study Am. J. Epidemiol., September 15, 2009; 170(6): 739 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Carbrey, L. Song, Y. Zhou, M. Yoshinaga, A. Rojek, Y. Wang, Y. Liu, H. L. Lujan, S. E. DiCarlo, S. Nielsen, et al. Reduced arsenic clearance and increased toxicity in aquaglyceroporin-9-null mice PNAS, September 15, 2009; 106(37): 15956 - 15960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Schumacher, D. P. McEwen, L. Zhang, K. L. Arendt, K. M. Van Genderen, and J. R. Martens Antiarrhythmic Drug-Induced Internalization of the Atrial-Specific K+ Channel Kv1.5 Circ. Res., June 19, 2009; 104(12): 1390 - 1398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Abbott and T. K. Roepke HERG biosynthesis: the positive influence of negative charge Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1211 - H1212. [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. McEwen and J. R. Martens Antifibrillatory Agents and Potassium Channels in the Atria: Pore Block versus Channel Trafficking Mol. Interv., April 1, 2009; 9(2): 79 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Wang, A. T. Dennis, P. Trieu, F. Charron, N. Ethier, T. E. Hebert, X. Wan, and E. Ficker Intracellular Potassium Stabilizes Human Ether-a-go-go-Related Gene Channels for Export from Endoplasmic Reticulum Mol. Pharmacol., April 1, 2009; 75(4): 927 - 937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Guasti, O. Crociani, E. Redaelli, S. Pillozzi, S. Polvani, M. Masselli, T. Mello, A. Galli, A. Amedei, R. S. Wymore, et al. Identification of a Posttranslational Mechanism for the Regulation of hERG1 K+ Channel Expression and hERG1 Current Density in Tumor Cells Mol. Cell. Biol., August 15, 2008; 28(16): 5043 - 5060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Myokai, S. Ryu, H. Shimizu, and S. Oiki Topological Mapping of the Asymmetric Drug Binding to the Human Ether-a-go-go-Related Gene Product (HERG) Potassium Channel by Use of Tandem Dimers Mol. Pharmacol., June 1, 2008; 73(6): 1643 - 1651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Roden, P. Kannankeril, and D. Darbar On the relationship among QT interval, atrial fibrillation, and torsade de pointes Europace, September 1, 2007; 9(suppl_4): iv1 - iv3. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Guo, H. Massaeli, W. Li, J. Xu, T. Luo, J. Shaw, L. A. Kirshenbaum, and S. Zhang Identification of IKr and Its Trafficking Disruption Induced by Probucol in Cultured Neonatal Rat Cardiomyocytes J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 911 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wang, B. A. Wible, X. Wan, and E. Ficker Cardiac Glycosides as Novel Inhibitors of Human Ether-a-go-go-Related Gene Channel Trafficking J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 525 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. A. Kuryshev, L. Wang, B. A. Wible, X. Wan, and E. Ficker Antimony-Based Antileishmanial Compounds Prolong the Cardiac Action Potential by an Increase in Cardiac Calcium Currents Mol. Pharmacol., April 1, 2006; 69(4): 1216 - 1225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Katchman, J. Koerner, T. Tosaka, R. L. Woosley, and S. N. Ebert Comparative Evaluation of HERG Currents and QT Intervals following Challenge with Suspected Torsadogenic and Nontorsadogenic Drugs J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1098 - 1106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Hamlin A Search to Predict Potential for Drug-Induced Cardiovascular Toxicity Toxicol Pathol, January 1, 2006; 34(1): 75 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Gintant, Z. Su, R. L. Martin, and B. F. Cox Utility of hERG Assays as Surrogate Markers of Delayed Cardiac Repolarization and QT Safety Toxicol Pathol, January 1, 2006; 34(1): 81 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. S. Choi, A. Khurana, R. Mathur, V. Viswanathan, D. F. Steele, and D. Fedida Kv1.5 Surface Expression Is Modulated by Retrograde Trafficking of Newly Endocytosed Channels by the Dynein Motor Circ. Res., August 19, 2005; 97(4): 363 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. A. Kuryshev, E. Ficker, L. Wang, P. Hawryluk, A. T. Dennis, B. A. Wible, A. M. Brown, J. Kang, X.-L. Chen, K. Sawamura, et al. Pentamidine-Induced Long QT Syndrome and Block of hERG Trafficking J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 316 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Thomas, B. C. Hammerling, A.-B. Wimmer, K. Wu, E. Ficker, Y. A. Kuryshev, D. Scherer, J. Kiehn, H. A. Katus, W. Schoels, et al. Direct block of hERG potassium channels by the protein kinase C inhibitor bisindolylmaleimide I (GF109203X) Cardiovasc Res, December 1, 2004; 64(3): 467 - 476. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
